Plaque.Plus.

Seeing More of What Matters

SCCT2023 | Booth 200

 

As a leader in AI-applied technology and a Diamond Partner of SCCT, Cleerly is proud to support and provide exceptional education in cardiovascular CT at this year’s annual scientific meeting.

This year we are highlighting our Plaque Plus analysis to bring attention to the critical role that precisely quantifying plaque can play in comprehensive heart care and preventing heart attacks. Our AI-enabled CCTA analysis goes beyond calcium scoring, stress tests or any other marker – to truly see and identify all types of plaque, stage of coronary artery disease, stenoses, plaque burden, and how heart health changes over time for better disease tracking.

SCCT2023 Hynes Convention Center

 

 

Connect with the Cleerly team at

Booth #200

— or —

Book a meeting

 

Schedule Now

Join our lunch symposium in ROOM 312

 

Cleerly: An End-to-End AI Solution for Precision Heart Care

 

Friday, July 28, 11:55AM — 12:45PM
Complimentary lunch will be provided

 

 

Our panel of physician leaders will discuss how Cleerly’s AI-enabled CCTA analysis quantifies atherosclerosis, including its four-tiered plaque staging system, and the extensive research supporting its value and efficacy.

Symposium Speakers

Jim Min, CEO and Founder, Cleerly

James K. Min, MD
Founder and CEO, Cleerly

Andrew Choi, MD

Andrew Choi, MD, MSCCT
Co-Director of Multimodality Cardiac Imaging and Associate Professor of Medicine and Radiology, The George Washington University School of Medicine and Health Sciences and The GW Heart and Vascular Institute

Subha V. Raman, MD, MSEE, FACC, FAHA, FSCMR

Subha V. Raman, MD, MSEE, FACC, FAHA, FSCMR
Zipes-Medtronic Chair & Chief, IUSM Division of Cardiovascular Medicine, Physician Director, IUH/IUSM Cardiovascular Institute, VP for IU Health Cardiovascular Services

Ricardo Cury, MD

Moderator: Ricardo Cury, MD
Chairman, Radiology Associates of South Florida

 

Join Cleerly at these SCCT2023 events:

Thursday, July 27th
9:00AM – 11:45AM
AI/ML Hands-On Workshop

Hands On: Imaging Problems and Solutions through AI/ML Model Assessment
In this pre-conference workshop, learn how artificial intelligence and machine learning (ML) are disrupting the field. Join Cleerly CMO Dr. James P. Earls while he presents at the first "hands on" portion of the workshop Thursday morning.

4:00PM – 4:15PM
AI/ML Hands-On Workshop

Leveraging AI for Comprehensive, Standardized, and Personalized Cardiovascular Care
After the lunch break, Cleerly founder and CEO Dr. James K. Min will present at the second portion of the workshop, titled "The Role of AI/ML in Cardiovascular Imaging."

Friday, July 28th
7:55AM – 9:30AM
Opening Session

Cleerly Clinical Trials and Registries Award Presentation
General Session Rooms (302/304)
Dr. James K. Min will present the SCCT plaque and Cleerly award to the winner. Followed by the recipient’s speech and a moderated Q&A.

11:55AM – 12:45PM

Lunch Symposium: Cleerly: An End-to-End AI Solution for Precision Heart Care
Room 312
A panel discussion about the critical need for adoption of AI in CCTA analysis to achieve personalized, precision heart care and the research supporting it: 10 million images gathered over a 15-year-period in multi-center clinical trials.

5:05PM – 6:00PM

Novel Technologies
General Session Rooms (302/304)
Cleerly executives will join other SCCT Diamond Partners to present their view of the future and what Cleerly believes are the most important aspects of improving cardiovascular CT technology growth and quality.

SCCT2023 Hynes Convention Center

 

 

Connect with the Cleerly team at

Booth #200

during General Expo hours:
Friday from 9AM — Noon & 1PM — 7:45PM
Saturday from 9AM — Noon & 1PM — 5PM

— or —

Book a private meeting

 

Schedule Now
Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2024 Cleerly, Inc.